![Michal Silverberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michal Silverberg
Direktor/Vorstandsmitglied bei
ICL GROUP LTD
Profil
Michal Silverberg is currently Director at ICL Group Ltd. since 2022, Director at Viamet Pharmaceuticals, Inc., Director at Fore Biotherapeutics, Inc., Director at ImmPACT-Bio Ltd. since 2019, Director at Redona Therapeutics, Inc., Director at Nautic & Art, Inc., and Managing Partner at Novartis Venture Fund.
Former roles include Independent Non-Executive Director at Forma Therapeutics Holdings, Inc. from 2017 to 2020, Senior Director-New Product Commercialization at Novo Nordisk, Inc. from 2007 to 2013, Independent External Director at Enzymotec Ltd. from 2015 to 2017, Director at Adicet Therapeutics, Inc., Director at BiomX Ltd., Managing Director at Novartis Venture Funds (USA), and Senior Partner at Takeda Ventures, Inc. from 2014 to 2017.
Education includes graduate studies at The Trustees of Columbia University in The City of New York, an MBA from Tel-Aviv University, and undergraduate studies at the University of Haifa.
Aktive Positionen von Michal Silverberg
| Unternehmen | Position | Beginn |
|---|---|---|
| ICL GROUP LTD | Direktor/Vorstandsmitglied | 01.07.2022 |
ImmPACT-Bio Ltd.
 ImmPACT-Bio Ltd. BiotechnologyHealth Technology Develops novel strategy for improving current CAR-T therapies and for addressing this unmet need for solid cancers | Direktor/Vorstandsmitglied | 14.10.2019 |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Direktor/Vorstandsmitglied | - |
Nautic & Art, Inc.
 Nautic & Art, Inc. Recreational ProductsConsumer Durables Manufactures inflatable boats made in military-grade hypalon | Direktor/Vorstandsmitglied | - |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics for cancer and autoimmune diseases | Direktor/Vorstandsmitglied | - |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops inhibitors of validated metalloenzymes | Direktor/Vorstandsmitglied | - |
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Michal Silverberg
| Unternehmen | Position | Ende |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 18.06.2020 |
| ENZYMOTEC LTD. | Direktor/Vorstandsmitglied | 01.10.2017 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Michal Silverberg
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
46
Beziehungen ersten Grades
17
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 17 |
|---|---|
ICL Group Ltd.
 ICL Group Ltd. Chemicals: AgriculturalProcess Industries Produces and markets fertilizers and chemical products | Process Industries |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops inhibitors of validated metalloenzymes | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes novel therapeutics to transform the patient living | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures invests in companies located across the globe. The firm focuses on high-caliber, therapeutic, platform-based companies. It provides financing for early stage capital requirements. | Finance |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Develops biological medicines | Health Technology |
Enzymotec Ltd.
 Enzymotec Ltd. BiotechnologyHealth Technology Develops, manufactures and markets lipid-based bioactive ingredients | Health Technology |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
University of Haifa
 University of Haifa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Health Technology |
BiomX Ltd.
 BiomX Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs for cancer treatment | Health Technology |
ImmPACT-Bio Ltd.
ImmPACT-Bio Ltd. BiotechnologyHealth Technology Develops novel strategy for improving current CAR-T therapies and for addressing this unmet need for solid cancers | Health Technology |
Redona Therapeutics, Inc.
Redona Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics for cancer and autoimmune diseases | Health Technology |
Nautic & Art, Inc.
Nautic & Art, Inc. Recreational ProductsConsumer Durables Manufactures inflatable boats made in military-grade hypalon | Consumer Durables |
